Nosocomial pneumonia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Nosocomial pneumonia - Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Nosocomial pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nosocomial pneumonia: Overview
Nosocomial pneumonia, also known as Hospital-acquired pneumonia (HAP) is a common nosocomial bacterial infection and is most prevalent in medical and surgical intensive care units (ICUs). It is defined as pneumonia that occurs 48 hours or more after hospital admission and not incubating at the admission time. Signs and symptoms of indication may include cough, expectoration, a rise in body temperature, chest pain, fever, tachypnea, and/or crackles. Imaging studies for the diagnosis or exclusion of Nosocomial pneumonia include chest radiographs, CT, and Chest ultrasound. Early initiation of adequate empiric antibiotic therapy for the management of Nosocomial pneumonia, is associated with improved survival compared with initial inadequate therapy.
'Nosocomial pneumonia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nosocomial pneumonia pipeline landscape is provided which includes the disease overview and Nosocomial pneumonia treatment guidelines. The assessment part of the report embraces, in depth Nosocomial pneumonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Nosocomial pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nosocomial pneumonia Emerging Drugs
Further product details are provided in the report..
Nosocomial pneumonia: Therapeutic Assessment
This segment of the report provides insights about the different Nosocomial pneumonia drugs segregated based on following parameters that define the scope of the report, such as:
Nosocomial pneumonia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nosocomial pneumonia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nosocomial pneumonia drugs.
Nosocomial pneumonia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Nosocomial pneumonia - Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Nosocomial pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nosocomial pneumonia: Overview
Nosocomial pneumonia, also known as Hospital-acquired pneumonia (HAP) is a common nosocomial bacterial infection and is most prevalent in medical and surgical intensive care units (ICUs). It is defined as pneumonia that occurs 48 hours or more after hospital admission and not incubating at the admission time. Signs and symptoms of indication may include cough, expectoration, a rise in body temperature, chest pain, fever, tachypnea, and/or crackles. Imaging studies for the diagnosis or exclusion of Nosocomial pneumonia include chest radiographs, CT, and Chest ultrasound. Early initiation of adequate empiric antibiotic therapy for the management of Nosocomial pneumonia, is associated with improved survival compared with initial inadequate therapy.
'Nosocomial pneumonia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nosocomial pneumonia pipeline landscape is provided which includes the disease overview and Nosocomial pneumonia treatment guidelines. The assessment part of the report embraces, in depth Nosocomial pneumonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nosocomial pneumonia R&D. The therapies under development are focused on novel approaches to treat/improve Nosocomial pneumonia.
This segment of the Nosocomial pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nosocomial pneumonia Emerging Drugs
- Suvratoxumab: AstraZeneca
- Tosatoxumab: Aridis Pharmaceuticals
Further product details are provided in the report..
Nosocomial pneumonia: Therapeutic Assessment
This segment of the report provides insights about the different Nosocomial pneumonia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nosocomial pneumonia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Nosocomial pneumonia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nosocomial pneumonia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nosocomial pneumonia drugs.
Nosocomial pneumonia Report Insights
- Nosocomial pneumonia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nosocomial pneumonia drugs?
- How many Nosocomial pneumonia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nosocomial pneumonia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nosocomial pneumonia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nosocomial pneumonia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck & Co
- Clarametyx Biosciences
- Aridis Pharmaceuticals
- Clarametyx Biosciences
- Nabriva Therapeutics
- Hoth Therapeutics
- Helperby Therapeutics
- AstraZeneca
- Tedizolid
- Tosatoxumab
- Panobacumab
- Lefamulin
- CMTX 101
- AR 401
- HT-006
- HY-012B5
- HY-015B12
- Suvratoxumab
Introduction
Executive Summary
Nosocomial pneumonia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nosocomial pneumonia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nosocomial pneumonia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nosocomial pneumonia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tosatoxumab: Aridis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Suvratoxumab: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Lefamulin: Nabriva Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
CMTX 101 Clarametyx Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Nosocomial pneumonia Key Companies
Nosocomial pneumonia Key Products
Nosocomial pneumonia- Unmet Needs
Nosocomial pneumonia- Market Drivers and Barriers
Nosocomial pneumonia- Future Perspectives and Conclusion
Nosocomial pneumonia Analyst Views
Nosocomial pneumonia Key Companies
Appendix
Executive Summary
Nosocomial pneumonia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nosocomial pneumonia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nosocomial pneumonia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nosocomial pneumonia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tosatoxumab: Aridis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Suvratoxumab: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Lefamulin: Nabriva Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
CMTX 101 Clarametyx Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Nosocomial pneumonia Key Companies
Nosocomial pneumonia Key Products
Nosocomial pneumonia- Unmet Needs
Nosocomial pneumonia- Market Drivers and Barriers
Nosocomial pneumonia- Future Perspectives and Conclusion
Nosocomial pneumonia Analyst Views
Nosocomial pneumonia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Nosocomial pneumonia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nosocomial pneumonia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nosocomial pneumonia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nosocomial pneumonia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
